Document is current
Any future updates will be listed below
-
Authors
Masuda, Hiroko
Nagai, Shigenori E. https://orcid.org/0000-0003-2887-6066
Hattori, Masaya
Yoshinami, Tetsuhiro
Okamura, Takuho
Watanabe, Kenichi
Nakayama, Takahiro
Tsuneizumi, Michiko
Takabatake, Daisuke
Harao, Michiko
Yoshino, Hiroshi
Mori, Natsuko
Yasojima, Hiroyuki
Oshiro, Chiya
Iwase, Madoka
Yamaguchi, Miki
Sangai, Takafumi
Sasada, Shinsuke
Ishida, Takanori
Futamura, Manabu
Oda, Hirotaka
Muramatsu, Yasuaki
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
-
Funding
Funding for this research was provided by:
Pfizer Inc. (Not applicable)
- License Information
-
More Information
Article History
Received: 18 August 2025
Accepted: 6 December 2025
First Online: 11 February 2026
Declarations
:
: HM reports honoraria from Eli Lilly, Chugai, and Pfizer. SN reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Eli Lilly, MSD, Taiho, Chugai, and Pfizer. MaHa reports honoraria from Eli Lilly and Pfizer. TY reports honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, MSD, and Pfizer. KW reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Shionogi, Kyowa-Kirin, Nippon-Kayaku, Novartis, Eli Lilly, Taiho, Chugai, and Pfizer. TN reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Novartis, Eli Lilly, Taiho, Chugai, and Pfizer. MY reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Nippon-Kayaku, Eli Lilly, Taiho, Chugai, and Pfizer. TS reports honoraria from Chugai, Novartis, MSD, Taiho, Eisai, Maruho, PDRadiopharma, Nippon-Kayaku, Kyowa-Kirin, AstraZeneca, Eli Lilly, Daiichi-Sankyo and Pfizer; and institutional support from Taiho. TI reports honoraria from Chugai, and Pfizer. MF reports honoraria from Chugai, Taiho, Eisai, Nippon-Kayaku, Eli Lilly, and Daiichi-Sankyo. HO is an employee of Pfizer Inc. and stockholder in Pfizer Inc. YM is an employee of Pfizer Inc. and stockholder in Pfizer Inc. NoMa reports honoraria from Chugai, Pfizer, AstraZeneca, Eli Lilly, and Daiichi-Sankyo; and institutional support from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa-Kirin, and Nippon-Kayaku. TO, MT, DT, MiHa, HiYo, NaMo, HiYa, CO, MI, and SS have no disclosures.
: The study used for this analysis was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and the Institutional Review Board (IRB) regulations. Clinical study protocols, informed consent forms, and other study-related documents were reviewed and approved by the relevant local or central institutional review board. Informed consent was obtained from all individual participants included in the study.
